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Oesophageal cancer is still associated with poor prognosis. The 
progress in systemic treatment, radiation therapy and surgery 
over the last decades has resulted in only moderate improvement 
of survival. Neoadjuvant chemoradiotherapy (CRT) 
has been shown to be associated with tumour response in 
60–70% of patients (1), and with complete pathological 
response (CPR) in 25–30% of patients (2,3). Although it 
reportedly improves survival, there are several concerns 
about its routine use. Besides the treatment-related toxicity, 
the most important issue is lack of reliable predictive factors 
for pathological tumour and nodal response. In fact, in non-
responders the neoadjuvant therapy is harmful, as it delays 
alternative, potentially effective treatment. Progression during 
the neoadjuvant therapy is not rare in this subset of patients.
Ideally, if we were able to predict response to particular 
therapies, we could select them individually for each patient. 
This goal is unlikely to be achieved in near future, due to 
the complexity of each individual clinical situation, including 
genetic and phenotypic variability of particular tumour clones 
and multiple patient-related factors. More realistic concept 
was designed and evaluated by the authors from Munich, 
showing for the first time feasibility of assessment of the 
metabolic response after first cycle of adjuvant therapy (4-6). 
Their milestone work paved the way for research programs, 
which, hopefully, will bring us closer to the individualised 
treatment of patients with oesophageal cancer.
Among these new approaches one very promising 
is development of more advanced composite metrics, 
combining volumetric measurements with basic and relative 
changes in metabolic activity. Recently, authors from the 
Oxford University published in the Journal of Nuclear 
Medicine results of the study, aimed at evaluation of several 
such metrics (7). The authors proposed assessment of:
(I) Metabolic nodal response (mNR);
(II) Metabolic tumour volume (MTV);
(III) Tumour glycolytic volume (TGV). 
The rationale for using the metabolic response in lymph 
nodes rather than in the primary tumour is that most 
relapses after curative-intent treatment of oesophageal 
cancer are regional and distant metastases, caused by the 
highly aggressive clones of malignant cells. The authors 
provided evidence supporting the assumption that response 
of these cell lines to the neoadjuvant treatment is more 
important predictive factor than response in the primary 
tumour itself. On a molecular level, this can be explained by 
the expression on GLUT-1 receptors. As shown by Hiyoshi 
et al. and Patching et al., overexpression of GLUT-1 in the 
lymph node metastases correlates with risk of relapse and is 
negative prognostic factor (8,9).
The Oxford group determined the MTV using a fixed 
SUV threshold of ≥4. On the other hand, the TGV was 
calculated as the product of MTV and SUV. Using SUVmean, 
the TGVmean was calculated, whilst using the SUVmax 
the TGVmax was produced. All these metrics can be 
calculated as baseline values or, ideally, as a composite 
metric such as ΔMTV, ΔTGVmax and ΔTGVmean (7). 
Combination of spatial data with metabolic response 
resulted in improved prediction.
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The study by Findlay et al. has of course limitations, 
some of them discussed by the authors. These include the 
retrospective character of the study and data collection 
over a long period of time. Additionally, in 301 patients 
11 different chemotherapy (CTH) regimens were used, 
and T stage was recorded using 7th edition of the TNM 
system, whilst, N stage—using 6th edition. Certainly, this 
heterogeneity could have an impact on the results. What 
even more important, the study considered patients who 
underwent neoadjuvant CTH only. However, current 
evidence shows that effectiveness of neoadjuvant CTH is 
significantly lower that of CRT. The authors cite papers 
showing minimal or no pathological response in 60% of 
patients after neoadjuvant CTH (10,11) vs. 30–40% of those 
who underwent neoadjuvant CRT (1). So, the results noted 
in patients who underwent only CTH may not be directly 
applied to the CRT cohort and therefore may not be 
relevant to most patients treated nowadays for oesophageal 
cancer.
Nevertheless, Findlay et al. indicate new philosophy 
in predictive and prognostic factors in patients treated 
for oesophageal cancer. The volumetric-metabolic 
measurements and analysis of mNR may provide new, useful 
way to individualised therapy. Despite all the limitations, 
the study of Findlay et al. may be the next milestone in 
research aimed at answering the fundamental question: 
which therapy is optimal for which patient? This approach 
warrants further investigation, optimally in prospective, 
multicentre trials, enabling enrolment of sufficiently large 
group of patients evaluated and treated in a uniform, 
protocol-based manner.
Will this turn to be a new hope for patients with oesophageal 
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